

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

INSIDE INFORMATION – SUBSTANTIAL REDUCTION IN LOSS

This announcement is made by New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) (“**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (“**Directors**”) of the Company (“**Board**”) wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that, based on a preliminary review and analysis of the latest available unaudited consolidated management accounts of the Company, it is expected that the Group will record a net loss of not more than HK\$30.0 million for the year ended 31 December 2023 (“**FY 2023**”) as compared to the net loss of approximately HK\$77.9 million recorded by the Group for the year ended 31 December 2022 (“**FY 2022**”).

The expected substantial reduction in loss for FY 2023 was primarily due to (i) the absence of equity-settled share-based payment expenses. Such expenses for FY 2022 amounted to approximately HK\$10.4 million which was recognised as a result of the grant of share options by the Group to the Directors and employees during FY 2022 and the Group did not record such expenses for FY 2023; and (ii) the recognition of the impairment loss on inventories of approximately HK\$1.6 million due to the slow-moving inventories that were close to their expiry date as compared to the impairment loss on inventories of approximately HK\$42.4 million for FY 2022.

The Company is still in the process of preparing and finalising its unaudited consolidated financial statements for FY 2023. The information contained in this announcement is only based on a preliminary assessment made by the Board with reference to the information currently available, which has not been reviewed or audited by the auditors of the Company and may be subject to change or adjustments. Shareholders and potential investors are advised to refer to the details of the Group's financial results for FY 2023, which are expected to be published in late March 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman & Executive Director

Hong Kong, 15 March 2024

As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.